{"prompt": "['11. SPECIAL STUDIES (NON-TISSUE)', '11.1', 'The Expanded Prostate Cancer Index Composite (EPIC; required assessment)', 'Health Related Quality of Life as measured by the EPIC questionnaire is the primary', 'endpoint in this study. Therefore, every randomized, eligible, analyzable patient on the', 'study will complete the EPIC. Patients will complete the EPIC per the schedule in', 'Section 4.', '11.1.1 The EPIC is a prostate cancer health-related quality of life (HRQOL) patient self-', 'administered instrument that measures a broad spectrum of urinary, bowel, sexual, and', 'hormonal symptoms related to prostate cancer treatments, including prostatectomy,', 'radiotherapy, and hormonal therapy (van Andel 2003). Instrument development was', 'based on advice from an expert panel and prostate cancer patients, which led to', 'expanding the 20-item University of California-Los Angeles Prostate Cancer Index', '(UCLA-PCI) to the 50-item EPIC. Summary and subscale scores were derived by content', 'and factor analyses. Test-retest reliability and internal consistency were high for EPIC', 'urinary, bowel, sexual, and hormonal domain summary scores (each r > 0.80 and', \"Cronbach's alpha > 0.82) and for most domain-specific subscales. Correlations between\", 'function and bother subscales within domains were high r > 0.60). Correlations between', 'different primary domains were consistently lower, indicating that these domains assess', 'distinct HRQOL components. The domains were validated separately, and because each', 'domain will be used intact, there is no threat to validity.', 'Response options for each item form a Likert scale with scores transformed linearly to a', '0-100 scale. Domain scores are also on a 0-100 scale with higher scores representing', 'better HRQOL. Some items have 5 response options while others have 4. The bowel', 'domain contains 14 questions, the urinary domain contains 12 items, the sexual domain', 'contains 13 questions, and the hormonal domain contains 11 questions.', '11.1.2 EuroQol (EQ-5D)', 'The EQ-5D is a 6-item validated utility assessment instrument that takes less than', '5', 'minutes to complete (van Agt 1994, Conner-Spady 2001, Brooks 1991, Nord 1991). The', 'first part consists of 5 items covering 5 dimensions including: mobility, self-care, usual', 'activities, pain/discomfort, and anxiety/depression. Each dimension is graded on 5 levels:', '1-no problems, 2-slight problems, 3-moderate problems, 4-severe problems, and 5-unable', 'to perform/extreme problems. Health states are defined by the combination of the leveled', 'responses to the 5 dimensions, generating 3, 125 health states. The sixth item is a visual', 'analogue scale for overall health. The 5-item index score is transformed into a utility score', 'between 0, \"Worst health state,\" and 1, \"Best health state.\" The index score can be used in', 'a quality adjusted survival analysis depending on the health state(s) of interest (Wu 2002).', 'For this study we plan to report the multidimensional utilities for comparative purposes.', 'The measured utility values for each patient on this study will be combined with overall', 'survival to calculate the \"QALY\" quality-adjusted life years. This will then be used for', 'cost-effectiveness analysis comparing the two arms in this trial. Patients will complete the', 'EQ-5D as specified in the Study Parameter Table in Section 4.', 'NRG-GU003', '39', 'Version Date: April 26, 2019']['12.', 'MODALITY REVIEWS', '12.1', 'Radiation Therapy Quality Assurance Reviews(26-APR-2019)', 'The Principal Investigator, Mark Buyyounouski, M.D. and his designee(s), will perform a', 'RT Quality Assurance Review after IROC Philadelphia-RT has received complete data in', 'TRIAD for the cases enrolled. The reviews will be completed remotely and will be ongoing.', 'The final cases will be reviewed within 3 months after this study has reached the target', 'accrual or as soon as IROC Philadelphia-RT has received complete data in TRIAD for all', 'cases enrolled, whichever occurs first. The scoring mechanism is: Per Protocol,', 'Acceptable Variation, and Unacceptable Deviation.', '13.', 'DATA AND RECORDS', '13.1', 'Data Management/Collection (26-APR-2019)', 'Data collection for this study will be done exclusively through Medidata RaveR. Access', 'to the trial in Rave is granted through the iMedidata application to all persons with the', 'appropriate roles in RSS (Regulatory Support System). To access iMedidata/Rave, the', 'site user must have an active CTEP-IAM account and the appropriate Rave role (Rave', 'CRA, Rave Read-Only, Rave CRA (Lab Admin), Rave SLA or Rave Investigator) on', 'either the LPO or participating organization rosters at the enrolling site. To the hold Rave', 'CRA role or Rave CRA (Lab Admin) role, the user must hold a minimum of an AP', 'registration type. To hold the Rave Investigator role, the individual must be registered as', 'an NPIVR or IVR. Associates can hold read-only roles in Rave.', 'Upon initial site registration approval for the study in RSS, all persons with Rave roles', 'assigned on the appropriate roster will be sent a study invitation e-mail from iMedidata', '(iMedidata-Notification@mdsol.com) to activate their account. To accept the invitation,', 'site users must log into the Select Login (https://login.imedidata.com/selectlogin) using', 'their CTEP-IAM user name and password, and click on the \"accept\" link in the upper', 'right-corner of the iMedidata page. Please note, site users will not be able to access the', 'study in Rave until all required Medidata and study specific trainings are completed.', 'Trainings will be in the form of electronic learnings (eLearnings) and will be listed in the', 'upper right pane of the iMedidata screen.', 'Users that have not previously activated their iMedidata/Rave accounts also will receive a', 'separate invitation from iMedidata to activate their account. Account activation', 'instructions are located on the CTSU website, Rave tab under the Rave resource materials', '(Medidata Account Activation and Study Invitation Acceptance). Additional information', 'on iMedidata/Rave is available on the CTSU website under the Rave tab at', 'www.ctsu.org/RAVE/or by contacting the CTSU Help Desk at 1-888-823-5923 or by e-', 'mail at ctsucontact@westat.com.', '13.2', 'Summary of Data Submission', 'Adverse event data collection and reporting, which are required as part of every clinical', 'trial, are done to ensure the safety of patients enrolled in the studies as well as those who', 'will enroll in future studies using similar agents. Adverse events are reported in a routine', 'manner at scheduled times during the trial using Medidata Rave\u00ae. Additionally, certain', 'adverse events must be reported in an expedited manner for more timely monitoring of', 'patient safety and care. See Section 7.3 for information about expedited and routine', 'reporting.', 'NRG-GU003', '40', 'Version Date: April 26, 2019']\n\n###\n\n", "completion": "END"}